{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-038861","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2025-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.087189+00:00","generated_at":"2026-05-24T21:17:47.665727+00:00","sec_items":["5.07","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Jaguar Health shareholders OK reverse stock split; crofelemer POC data and FDA meeting expected Q2 2025","bullets":["Shareholders voted 5,281,329 for and 1,377,494 against the reverse stock split (ratio 1:15 to 1:40); board to set exact ratio by March 2026.","First proof-of-concept investigator-initiated trial results for crofelemer in SBS-IF and MVID are expected in Q2 2025.","Company expects FDA meeting in Q2 2025 to discuss Phase 3 OnTarget breast cancer subgroup results and potential approval path.","Adjournment proposal also approved with 5,423,671 for and 1,163,222 against."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-038861","json":"https://secwatch.observer/filing/0000950170-25-038861.json","markdown":"https://secwatch.observer/filing/0000950170-25-038861.md","text":"https://secwatch.observer/filing/0000950170-25-038861.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000095017025038861/0000950170-25-038861-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000095017025038861/jagx-20250313.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T21:17:47.665727+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}